Overview

A Phase 2, Dose Finding Study of PF-03187207 in Patients With Primary Open Angle Glaucoma or Ocular Hypertension.

Status:
Completed
Trial end date:
2008-06-01
Target enrollment:
Participant gender:
Summary
To investigate dose response, safety and efficacy of PF-03187207 in patients with primary open-angle glaucoma or ocular hypertension
Phase:
Phase 2
Details
Lead Sponsor:
Bausch & Lomb Incorporated
Treatments:
Latanoprost